Last update 16 May 2025
M's Science Corp.

M's Science Corp.

Holding Company|2000|Tokyo-to, Japan|
m-sci.com

Overview

Tags

Nervous System Diseases
Other Diseases
Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Hemic and Lymphatic Diseases1
Immune System Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
σ1 receptor(Sigma opioid receptor)1

Related

1
Drugs associated with M's Science Corp.
Cutamesine Hydrochloride
Target
σ1 receptor
Mechanism
σ1 receptor agonists
Active Org.
Santen SAS [+2]
Originator Org.
Santen SAS
Active Indication
Amyotrophic Lateral Sclerosis [+3]
Inactive Indication
Acute Ischemic Stroke [+3]
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
4
Clinical Trials associated with M's Science Corp.
JPRN-jRCT2080223845
/ RecruitingPhase 2
ST-605 uncontrolled open-label phase 2 study in patients with herpes simplex virus keratitis
JPRN-jRCT2080223131
/ Unknown statusPhase 2
ST-605 phase 2 study - uncontrolled open-label study in patients with cytomegalovirus corneal endotheliitis -
NCT00639249
/ CompletedPhase 2
A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Phase IIa Study of Safety and Motor Function Restoration in Subjects Treated With SA4503 Following Acute Ischemic Stroke
100 Clinical Results associated with M's Science Corp.
Login to view more data
0 Patents (Medical) associated with M's Science Corp.
Login to view more data
100 Deals associated with M's Science Corp.
Login to view more data
100 Translational Medicine associated with M's Science Corp.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
3
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free